FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 168 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... August 8, 2025 ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After... July 2, 2021 How I Learned to Cope With Survivor’s Guilt After Cancer January 27, 2021 Coronavirus and COVID-19: What People With Cancer Need to Know June 21, 2020 Load more HOT NEWS Sun Exposure Lowers Risk of Breast Cancer, Study Finds 4 Ways to Avoid Comparing Yourself to Others on Social Media... FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and... 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected...
